ASSESS: A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg doses administered orally once daily or glatiramer acetate administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis
Aims: The purpose of this study is to compare 2 doses of fingolimod to copaxone and to evaluate the efficacy and safety of fingolimod 0.25mg
Principal Investigator: Afif Hentati, MD
IRB Approval Number: EH12-289
Funding Source: Novartis
Contact: Please call 847.570.1439 with questions regarding the study
Open to Enrollment: Yes

A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (dimethyl fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Aim: To assess patient reported outcomes for safety and quality of life issues for patients taking Tecfidera
Principal Investigator: Susan Rubin, MD
IRB Approval Number: EH13-416
Funding Source: Biogen, Idec.
Contact: Please call 847.570.1439 with questions regarding the study
Open to Enrollment: Yes

A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis BAF312A2304
Aim: The purpose of this study is to find out if the drug BAF312 (Siponimod) is safe and has beneficial effects in people who have Secondary Progressive Multiple Sclerosis (SPMS)
Principal Investigator: Susan Rubin, MD
IRB Approval Number: EH13-294
Funding Source: Novartis
Contact: Please call 847.570.1439 with questions regarding the study
Open to Enrollment: Yes

× Alternate Text